Carbidopa

Generic Name: Carbidopa

Brand Names: Dhivy, Duodopa, Duopa, Lodosyn, Parcopa, Rytary, Sinemet, Stalevo

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₄N_₂O_₄

CAS Number: 28860-95-9

Unique Ingredient Identifier: KR87B45RGH

Background: Carbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate. It potently inhibits aromatic amino acid decarboxylase (DDC) and due to its chemical properties, it does not cross the blood-brain barrier. Due to its activity, carbidopa is always administered concomitantly with levodopa. An individual formulation containing...

Indication: Carbidopa is indicated with levodopa for the treatment of symptoms of idiopathic Parkinson disease, postencephalitic parkinsonism and symptomatic parkinsonism followed by carbon monoxide or manganese intoxication.

The combination therapy is administered for the reduction of levodopa-driven nausea and vomiting.
...

Associated Conditions: Parkinson's Disease (PD), Parkinsonism post encephalitic, Symptomatic Parkinson Disease, Levodopa-driven nausea and vomiting

Associated Therapies: -

Clinical Trials

Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease

Not Applicable

Completed

Conditions: Effect of Drug
Parkinson Disease

Interventions: Drug: Opicapone 50 mg
Drug: Duodopa

First Posted Date: 2024-05-29

Last Posted Date: 2024-05-29

Lead Sponsor: University Hospital of Ferrara

Target Recruit Count: 22

Registration Number: NCT06432309

Locations: 🇮🇹
University Hospital of Ferrara - Arcispedale Sant'Anna, Ferrara, Emilia Romagna, Italy

Histaminergic Basis of Fatigue in Multiple Sclerosis

Phase 2

Withdrawn

Conditions: Multiple Sclerosis

Interventions: Drug: L-Histidine
Drug: Placebo
Drug: Lodosyn

First Posted Date: 2021-02-21

Last Posted Date: 2021-07-29

Lead Sponsor: University of Miami

Registration Number: NCT04764383

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Effects of 5HTP on the Injured Human Spinal Cord

Phase 2

Recruiting

Conditions: Spinal Cord Injuries

Interventions: Drug: Placebo
Drug: 5-Hydroxytryptophan 100 MG
Drug: 5-Hydroxytryptophan
Drug: Carbidopa

First Posted Date: 2020-08-20

Last Posted Date: 2024-08-09

Lead Sponsor: University of Alberta

Target Recruit Count: 30

Registration Number: NCT04520178

Locations: 🇺🇸
University of Louisville, Louisville, Kentucky, United States
🇨🇦
University of Alberta, Edmonton, Alberta, Canada

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System

Phase 1

Completed

Conditions: Parkinsonian Signs in Older Persons

Interventions: Drug: carbidopa

First Posted Date: 2020-03-27

Last Posted Date: 2024-04-04

Lead Sponsor: University of Michigan

Target Recruit Count: 14

Registration Number: NCT04325503

Locations: 🇺🇸
Functional Neuroimaging, Cognitive, and Mobility Lab, University of Michigan, Ann Arbor, Michigan, United States

Effects of 5HTP and LDOPA on CNS Excitability After SCI

Phase 2

Suspended

Conditions: Spinal Cord Injuries

Interventions: Drug: 5HTP
Drug: Placebo oral tablet
Drug: Carbidopa
Drug: L-DOPA

First Posted Date: 2019-06-27

Last Posted Date: 2022-10-17

Lead Sponsor: Jessica M D'Amico

Target Recruit Count: 30

Registration Number: NCT04000919

Locations: 🇺🇸
University of Louisville, Kentucky Spinal Cord Injury Research Centre, Louisville, Kentucky, United States

Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Sinemet
Drug: CVT-301

First Posted Date: 2019-03-25

Last Posted Date: 2019-08-02

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 23

Registration Number: NCT03887884

Locations: 🇺🇸
Acorda Site #1005, Hallandale Beach, Florida, United States
🇺🇸
Acorda Site #1004, Atlanta, Georgia, United States
🇺🇸
Acorda Site #1002, Orlando, Florida, United States

and more 2 locations

Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach

Phase 1

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Carbidopa
Dietary Supplement: L-Histidine

First Posted Date: 2017-08-30

Last Posted Date: 2020-10-08

Lead Sponsor: University of Miami

Target Recruit Count: 18

Registration Number: NCT03266965

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Norepinephrine-targeted Therapy for Action Control in Parkinson Disease

Phase 4

Completed

Conditions: Parkinson Disease

Interventions: Drug: Droxidopa
Drug: Carbidopa

First Posted Date: 2017-04-14

Last Posted Date: 2020-01-27

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 15

Registration Number: NCT03115827

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Dose-finding Pharmacokinetic Study in Healthy Males

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Levodopa
Drug: Carbidopa
Drug: ODM-104

First Posted Date: 2017-02-16

Last Posted Date: 2021-05-27

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 56

Registration Number: NCT03055936

Locations: 🇩🇪
Nuvisan Pharma Services, Neu-Ulm, Germany

A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease

Phase 2

Completed

Conditions: Advanced Parkinson's Disease

Interventions: Drug: Sinemet
Drug: IPX203

First Posted Date: 2017-01-02

Last Posted Date: 2022-06-06

Lead Sponsor: Impax Laboratories, LLC

Target Recruit Count: 28

Registration Number: NCT03007888

Locations: 🇺🇸
Site 114, Little Rock, Arkansas, United States
🇺🇸
Investigator 109, Cleveland, Ohio, United States
🇺🇸
Investigator 104, Spokane, Washington, United States

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy